IL-1b-Bearing NETs: Bridging Inflammation to Early Cirrhosis in Hepatitis B
International Journal of Molecular Sciences · 15.06.2025 · 26 (12) · 5733
DOI: 10.3390/ijms26125733 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.06.2025. Verfasst von Maria Ntinopoulou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Immunology, Department of Biological Applications & Technology, Faculty of Health Sciences, University of Ioannina, 45332 Ioa…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Extracellular Traps, Hepatitis B, Inflammation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences Hellas M.EPE., Hellenic Foundation for Research and Innovation (HFRI) under the 5th Call for HFRI PhD Fellowships.
Abstract (Originalsprache)
Hepatitis B virus (HBV) infection is one of the most dangerous viral diseases, with innate immunity representing the first line of defense against the virus. In this branch of the immune system, neutrophils are considered key cellular mediators. To better understand the implication of neutrophils in the distinct stages of the disease, HBV-infected patients were enrolled in this study and categorized into three groups: patients with acute infection, chronic infection under treatment, and at early cirrhotic stage. To elucidate the role of inflammatory mediators and cellular mechanisms of neutrophilic origin in the course of the infection, both ex vivo and in vitro studies were performed. Increased levels of C-C motif chemokine ligand 2 (CCL2), interleukin (IL)-18, IL-33, and citrullinated histone H3 (CitH3)—an accurate marker of neutrophil extracellular traps (NETs)—were detected in the circulation of patients with acute infection or early cirrhosis. In parallel, sera from the aforementioned patient groups induced the formation of IL-1b-bearing NETs in neutrophils from healthy individuals. These inflammatory NETs affected primary fibroblasts towards acquiring a pro-fibrotic phenotype. These results suggest that NETs could be regarded as mediators in hepatitis B manifestations, while their therapeutic targeting could enhance the management of early-stage cirrhotic patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Immunology, Department of Biological Applications & Technology, Faculty of Health Sciences, University of Ioannina, 45332 Ioannina, Greece.
- Laboratory of Microbiology, Department of Medicine, Faculty of Health Sciences, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- First Department of Internal Medicine, University General Hospital of Alexandroupolis, 68100 Alexadroupolis, Greece.
ORCID-Profile: Maria Ntinopoulou, Theocharis Konstantinidis, Aikaterini Skeva
Förderung
- Gilead Sciences Hellas M.EPE.
- Hellenic Foundation for Research and Innovation (HFRI) under the 5th Call for HFRI PhD Fellowships
Zitieren
APA
Ntinopoulou, M., Konstantinidis, T., Chalkidou, A., Papagianni, E., Skeva, A., Panopoulou, M., & Chrysanthopoulou, A. (2025). IL-1b-Bearing NETs: Bridging Inflammation to Early Cirrhosis in Hepatitis B. International Journal of Molecular Sciences, 26(12), 5733. https://doi.org/10.3390/ijms26125733
Vancouver
Ntinopoulou M, Konstantinidis T, Chalkidou A, Papagianni E, Skeva A, Panopoulou M, et al. IL-1b-Bearing NETs: Bridging Inflammation to Early Cirrhosis in Hepatitis B. International Journal of Molecular Sciences. 2025;26(12):5733. doi:10.3390/ijms26125733
BibTeX
@article{Ntinopoulou2025,
author = {Ntinopoulou, Maria and Konstantinidis, Theocharis and Chalkidou, Anna and Papagianni, Eleni and Skeva, Aikaterini and Panopoulou, Maria and Chrysanthopoulou, Akrivi},
title = {IL-1b-Bearing NETs: Bridging Inflammation to Early Cirrhosis in Hepatitis B},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {12},
pages = {5733},
doi = {10.3390/ijms26125733}
}
EUVIMED